Calamos Advisors
GBT

Calamos Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Calamos Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,086
Closed -$1.08M – 786
2020
Q1 		$1.08M Buy
+21,086
New +$1.41M 0.01% 592

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Calamos Advisors's GBT Position: Q2 2020 in Review

Calamos Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2020, closing a stake of 21,086 shares — an estimated $1.08M sold.

Calamos Advisors first reported a position in GBT in Q1 2020 and held it in 1 quarter. The position peaked at $1.08M in Q1 2020. 253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

  • Calamos Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Calamos Advisors sold 21,086 Global Blood Therapeutics, Inc. shares in Q2 2020, an estimated $1.08M.
  • Calamos Advisors first reported a position in Global Blood Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Calamos Advisors's Global Blood Therapeutics, Inc. position peaked at $1.08M in Q1 2020.
  • 253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.